IceCure Medical Presents Four Studies Supporting Broader Adoption of ProSense® at RSNA 2025
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 13 hour ago0mins
- International Recognition: At RSNA 2025, IceCure Medical had four independent study abstracts accepted, showcasing the effectiveness of ProSense® in 263 patients, further promoting the widespread adoption of this technology in breast cancer treatment.
- Clinical Data Support: One study demonstrated a 100% success rate in treating luminal cancers under 2.5 cm using ultrasound-guided cryoablation, indicating a safe and effective alternative for patients ineligible for surgery.
- Significant Treatment Outcomes: Another study comparing cryoablation combined with hormonal therapy to standalone treatments revealed an impressive 83.3% tumor reduction in the combination group, highlighting the added value of cryoablation.
- Increased Interest Post-FDA Approval: Following the FDA's marketing approval of ProSense® for low-risk breast cancer, IceCure Medical has observed a sustained increase in interest in the technology, indicating significant potential for broader applications in non-surgical treatment options.
ICCM.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCM is 2.75 USD with a low forecast of 2.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.695
Low
2.50
Averages
2.75
High
3.00
Current: 0.695
Low
2.50
Averages
2.75
High
3.00
H.C. Wainwright
Yi Chen
Buy
downgrade
$2
2025-08-15
Reason
H.C. Wainwright
Yi Chen
Price Target
$2
2025-08-15
downgrade
Buy
Reason
H.C. Wainwright analyst Yi Chen lowered the firm's price target on IceCure Medical to $2 from $2.50 and keeps a Buy rating on the shares post the Q2 report. The firm's projected shares outstanding in 12 months increased meaningfully as a result of IceCure's recent rights offering.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$2.5
2025-03-28
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2.5
2025-03-28
Reiterates
Strong Buy
Reason
See All Ratings
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?